Antiobesity Global Market Report 2023

Feb 2023| TBR553D| TBRC (Publisher)

Sample Report

Report Highlights

Including: 1) By Drug Class: Peripherally acting anti obesity drugs; Centrally acting anti obesity drugs
2) By Type: Prescription Drugs (Rx); OTC Drugs
3) By Medication: Monotherapies; Polytherapies
Covering: F. Hoffmann-La Roche AG; GlaxoSmithKline PLC; Boehringer Ingelheim GmbH; Pfizer Inc.; Merck & Co. Inc.

Antiobesity Global Market Report 2023 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antiobesity market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
Assess the Russia – Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Description:
Where is the largest and fastest growing market for antiobesity ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The antiobesity market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

Report Synopsis

Report Metrics	Details
Base year considered	2022
Forecast period considered	2022-2032
Units considered	$ Billion
Segments covered	By Drug Class, By Type, By Medication
Industry covered	Pharmaceuticals
Regions covered	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Countries covered	Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, Australia.
Companies studied	F. Hoffmann-La Roche AG; Rhythm Pharmaceuticals; GlaxoSmithKline PLC; Boehringer Ingelheim GmbH; Pfizer Inc.; Merck & Co. Inc.; Takeda Pharmaceuticals Company Limited; Eisai Co. Ltd.; Novo Nordisk A/S; Zafgen; Orexigen Therapeutics Inc. Zydus Cadila; Norgine B.V.; Vivus Therapeutics; Arena Pharmaceuticals Inc.;

Scope

Markets Covered:

By Drug Class: Peripherally acting anti obesity drugs; Centrally acting anti obesity drugs
By Type: Prescription Drugs (Rx); OTC Drugs
By Medication: Monotherapies; Polytherapies

Companies Mentioned: F. Hoffmann-La Roche AG; ; GlaxoSmithKline PLC; ; Boehringer Ingelheim GmbH

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery format: PDF, Word and Excel Data Dashboard.

Table 1 : Global Historic Market Growth, 2017-2022, $ Billion
Table 2 : Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
Table 3 : Global Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 4 : Global Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 5 : Global Anti-obesity Drugs Market, Segmentation By Medication, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 6 : Global Anti-obesity Drugs Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 7 : Global Anti-obesity Drugs Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 8 : Asia-Pacific, Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 9 : Asia-Pacific, Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 10 : China, Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 11 : China, Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 12 : India, Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 13 : India, Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 14 : Japan, Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 15 : Japan, Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 16 : Australia, Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 17 : Australia, Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 18 : Indonesia, Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 19 : Indonesia, Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 20 : South Korea, Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 21 : South Korea, Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 22 : Western Europe, Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 23 : Western Europe, Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 24 : UK, Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 25 : UK, Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 26 : Germany, Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 27 : Germany, Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 28 : France, Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 29 : France, Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 30 : Eastern Europe, Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 31 : Eastern Europe, Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 32 : Russia, Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 33 : Russia, Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 34 : North America, Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 35 : North America, Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 36 : USA, Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 37 : USA, Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 38 : South America, Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 39 : South America, Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 40 : Brazil, Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 41 : Brazil, Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 42 : Middle East, Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 43 : Middle East, Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 44 : Africa, Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 45 : Africa, Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 46 : F. Hoffmann-La Roche AG, Financial Performance
Table 47 : GlaxoSmithKline PLC, Financial Performance
Table 48 : Boehringer Ingelheim GmbH, Financial Performance
Table 49 : Pfizer Inc., Financial Performance
Table 50 : Merck & Co. Inc., Financial Performance

Figure 1 : Global Historic Market Growth, 2017-2022, $ Billion
Figure 2 : Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
Figure 3 : Global Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 4 : Global Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 5 : Global Anti-obesity Drugs Market, Segmentation By Medication, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 6 : Global Anti-obesity Drugs Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 7 : Global Anti-obesity Drugs Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 8 : Asia-Pacific, Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 9 : Asia-Pacific, Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 10 : China, Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 11 : China, Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 12 : India, Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 13 : India, Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 14 : Japan, Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 15 : Japan, Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 16 : Australia, Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 17 : Australia, Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 18 : Indonesia, Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 19 : Indonesia, Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 20 : South Korea, Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 21 : South Korea, Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 22 : Western Europe, Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 23 : Western Europe, Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 24 : UK, Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 25 : UK, Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 26 : Germany, Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 27 : Germany, Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 28 : France, Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 29 : France, Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 30 : Eastern Europe, Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 31 : Eastern Europe, Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 32 : Russia, Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 33 : Russia, Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 34 : North America, Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 35 : North America, Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 36 : USA, Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 37 : USA, Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 38 : South America, Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 39 : South America, Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 40 : Brazil, Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 41 : Brazil, Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 42 : Middle East, Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 43 : Middle East, Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 44 : Africa, Anti-obesity Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 45 : Africa, Anti-obesity Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 46 : F. Hoffmann-La Roche AG, Financial Performance
Figure 47 : GlaxoSmithKline PLC, Financial Performance
Figure 48 : Boehringer Ingelheim GmbH, Financial Performance
Figure 49 : Pfizer Inc., Financial Performance
Figure 50 : Merck & Co. Inc., Financial Performance

The Business Research Company is a market research and intelligence company which excels in company, market and consumer research. It has over 50 research professionals at its offices in India, the UK and the US as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Similar Reports from TBRC (Publisher)

Antiobesity Global Market Report 2022

Published Date - Mar 2022
Report Code - TBR553C

Including: 1) By Drug Class: Peripherally acting anti obesity drugs; Centrally acting anti obesity drugs
2) By Type: Prescription Drugs (Rx); OTC Drugs
3) By Medication: Monotherapies; Polytherapies
Covering: F.Hoffmann-La Roche AG; GlaxoSmithKline PLC.; Boehringer Ingelheim GmbH; Pfizer Inc.; Merck & Co. Inc.; Takeda Pharmaceuticals Company Limited

Antiobesity Global Market Report 2022 from The Business Research Company ...

Antiobesity Global Market Report 2021: COVID 19 Impact and Recovery to 2030

Published Date - Apr 2021
Report Code - TBR553B

Including: 1) By Drug Class: Peripherally acting anti obesity drugs; Centrally acting anti obesity drugs
2) By Type: Prescription Drugs (Rx); OTC Drugs
3) By Medication: Monotherapies; Polytherapies
Covering: F. Hoffmann-La Roche AG; GlaxoSmithKline PLC; Boehringer Ingelheim GmbH; Pfizer Inc.; Merck & Co. Inc.

Antiobesity Global Market Report 2021: COVID 19 Impact and Recovery to 2030 from ...

Antiobesity Drugs Global Market Report 2020

Published Date - Nov 2019
Report Code - TBR553A

Including: 1) By Drug Class: Peripherally acting anti obesity drugs, Centrally acting anti obesity drugs 2) By Type: Prescription Drugs (Rx), OTC Drugs 3) By Medication: Monotherapies, Polytherapies

Covering: F. Hoffmann-La Roche AG,, GlaxoSmithKline PLC,, Boehringer Ingelheim GmbH,, Pfizer Inc.,, Merck & Co. Inc.,

Antiobesity Drugs Market Global Report 2020 from The Business Research Company provides strategists, marketers and senior ...